FDA grants first generative-AI radiology tools breakthrough device status

breakthroughHealthcareRegulation

Thursday, June 25, 2026

Confidence

Medium · — validation data is preliminary and vendor-reported

Evidence

FDA Breakthrough Device Designation + company release with internal validation data

What happened

Cognita CXR is a generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted FDA Breakthrough Device Designation. The designation was announced by Mosaic Clinical Technologies earlier this year and re-surfaced this week alongside a parallel designation for Aidoc, with internal validation data reporting detection gains of 16–65% across certain findings and an 18% interpretation efficiency boost.

What it means

Breakthrough designation is not clearance — but it is the FDA telling two vendors they get the fast lane for a category (generative AI that drafts diagnostic findings, not just flags them) that did not have a regulatory playbook last year. Hospitals evaluating gen-AI radiology can now point procurement and legal at a federal signal instead of a vendor deck. The bigger shift: the FDA has implicitly accepted that a model authoring a preliminary report, with a radiologist signing it, is a device — which sets the template every gen-AI clinical tool will be measured against.

Sources